Clinical Trial Update: Doxil and Gemcitabine in Recurrent Ovarian Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Doxil (liposomal doxorubicin) with gemcitabine in recurrent ovarian cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Doxil (liposomal doxorubicin)
• Gemzar (gemcitabine)

Snippet

Sponsor: Women and Infants Hospital of Rhode Island | Conditions: Ovarian Carcinoma | Phase 2 | Status: TERMINATED